SCHEMBL5260587

SCHEMBL5260587

NC(=O)C(=Cc1c[nH]c2nc(OC(=O)c3ccccc3)ccc12)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 2/20 0.36
TAB1 Q15750 2/20 0.36
KMT2A Q03164 9/20 0.34
MAPT P10636 6/20 0.34
PARP10 Q53GL7 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
HPGD P15428 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
METAP2 P50579 1/20 0.33
METAP1 P53582 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
PARP1 P09874 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MEN1 O00255 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
CHEK1 O14757 2/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260583 1.00 MAP3K7 (0.36) MAP3K7TAB1KMT2AMAPTPARP10
SCHEMBL5261547 0.91 AKR1C1 (0.38) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL5260576 0.91 AKR1C1 (0.38) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL5261242 0.90 MAP3K7 (0.33) MAP3K7TAB1KMT2AHPGDKDM4E
SCHEMBL5261239 0.90 MAP3K7 (0.33) MAP3K7TAB1KMT2AHPGDKDM4E
SCHEMBL5263340 0.83 KMT2A (0.43) KMT2AMAPTSMN1; SMN2HPGDKDM4E
SCHEMBL5261833 0.82 ADORA2A (0.44) MAP3K7TAB1KMT2AMAPTSMN1; SMN2
SCHEMBL5259034 0.82 MAP3K7 (0.34) MAP3K7TAB1KMT2AMAPTSMN1; SMN2
SCHEMBL5259680 0.82 ADORA2A (0.42) MAP3K7TAB1KMT2AMAPTSMN1; SMN2
SCHEMBL5259677 0.82 ADORA2A (0.42) MAP3K7TAB1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP claimed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US claimed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US claimed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 MAP3K7 942/4885TAB1 3620/4885KMT2A 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.